Biohaven Pharmaceutical Holding Co Ltd.(BHVN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BHVN Biohaven Pharmaceutical Holding Co Ltd.

Post-Mkt 06-29 16:05:50 EDT

14.95

-0.88

-5.56%

盘后14.95

+0.000.00%

16:04 EDT

High15.25	Low14.05	Vol3.49M
Open14.32	D1 Closing15.83	Amplitude7.58%
Mkt Cap2.25B	Tradable Cap1.85B	Total Shares150.42M
T/O51.86M	T/O Rate2.81%	Tradable Shares124.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BHVN","market":"US","secType":"STK","nameCN":"Biohaven Pharmaceutical Holding Co Ltd.","latestPrice":14.95,"timestamp":1782763200000,"preClose":15.83,"halted":0,"volume":3488491,"hourTrading":{"tag":"盘后","latestPrice":14.95,"preClose":14.95,"latestTime":"16:04 EDT","volume":204,"amount":3052.0399199999997,"timestamp":1782763489939,"change":0,"changeRate":0,"amplitude":0.002676},"delay":0,"changeRate":-0.05559065066329759,"floatShares":124000000,"shares":150417084,"eps":-5.440705,"marketStatus":"Post-Mkt","change":-0.88,"latestTime":"06-29 16:05:50 EDT","open":14.32,"high":15.25,"low":14.05,"amount":51864309,"amplitude":0.075805,"askPrice":16.16,"askSize":3,"bidPrice":14.95,"bidSize":253,"shortable":0,"etf":0,"ttmEps":-5.440705,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1782777600000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1493870400000,"exchange":"NYSE","adjPreClose":15.83,"preHourTrading":{"tag":"盘前","latestPrice":14.05,"preClose":15.83,"latestTime":"09:26 EDT","volume":25652,"amount":369489.22758,"timestamp":1782739616797,"change":-1.78,"changeRate":-0.112445,"amplitude":0.133891},"postHourTrading":{"tag":"盘后","latestPrice":14.95,"preClose":14.95,"latestTime":"16:04 EDT","volume":204,"amount":3052.0399199999997,"timestamp":1782763489939,"change":0,"changeRate":0,"amplitude":0.002676},"volumeRatio":0.668468,"impliedVol":0.9593,"impliedVolPercentile":0.3426},"requestUrl":"/m/hq/s/BHVN/tweets","defaultTab":"tweets","newsList":[{"id":"2647830984","title":"Biohaven Shares Down as Phase 3 Trial Concerns Trigger Downgrade at Bofa","url":"https://stock-news.laohu8.com/highlight/detail?id=2647830984","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647830984?lang=en_us&edition=fundamental","pubTime":"2026-06-30 01:49","pubTimestamp":1782755340,"startTime":"0","endTime":"0","summary":"Shares of Biohaven retreated after they were downgraded by analysts at Bank of America on concerns about the upcoming readout from a Phase 3 trial for the company's epilepsy drug, known as Opakalim.The stock was down 6.3% at $14.84 in Monday afternoon trading. Shares have risen 31% this year.Even under the best case scenario, the analysts wrote, data for Biohaven's drug is likely to be undifferentiated when compared to Xenon Pharmaceuticals' investigative epilepsy treatment, known as azetukalnar.  Undifferentiated data would cast doubt on the consensus view that Biohaven could reach $1 billion in peak sales for the drug, they added.Biohaven's drug is identified Opakalim on the company's web site.\"Uncompelling Kv data could pressure shares given the company's cash runway concerns and the other sole 2026 catalyst  carries low derisking value,\" the analysts added.They downgraded the stock to underperform from neutral and cut its price target to $11 from $12.Write to Elias Schisgall at eli","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BHVN","BK4139","LU1093756325.SGD","LU1093756168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647703303","title":"Biohaven falls -9.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2647703303","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647703303?lang=en_us&edition=fundamental","pubTime":"2026-06-29 22:05","pubTimestamp":1782741929,"startTime":"0","endTime":"0","summary":"Biohaven (BHVN) is down -9.8%, or -$1.55 to $14.28. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/biohaven-falls-9-8-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/biohaven-falls-9-8-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1093756325.SGD","LU1093756168.USD","BHVN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647379322","title":"Biohaven Cut to Underperform from Neutral by B of a Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2647379322","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647379322?lang=en_us&edition=fundamental","pubTime":"2026-06-29 19:53","pubTimestamp":1782733980,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BHVN/analyst-ratings(END) Dow Jones NewswiresJune 29, 2026 07:53 ET","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BHVN","LU1093756325.SGD","LU1093756168.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647767403","title":"BofA Securities Downgrades Biohaven to Underperform From Neutral, $11 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2647767403","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647767403?lang=en_us&edition=fundamental","pubTime":"2026-06-29 19:41","pubTimestamp":1782733317,"startTime":"0","endTime":"0","summary":"BofA Securities Downgrades Biohaven to Underperform From Neutral, $11 Price Target","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1093756168.USD","LU1093756325.SGD","BHVN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647761213","title":"Biohaven Starts Pivotal Phase 3 Trial of Bhv-1300 in Graves' Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2647761213","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647761213?lang=en_us&edition=fundamental","pubTime":"2026-06-29 19:30","pubTimestamp":1782732647,"startTime":"0","endTime":"0","summary":"Biohaven starts pivotal Phase 3 trial of BHV-1300 in Graves' diseaseBiohaven began a pivotal Phase 3 trial of BHV-1300 in Graves’ disease, marking the first patient enrolled on June 29, 2026.Prior ear","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nNDL5YXBTX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BHVN","BK4139","LU1093756168.USD","LU1093756325.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647737697","title":"Biohaven Advances a New Class of Precision Immunology Therapies: First Mode Extracellular Protein Degrader, Bhv-1300, Begins Phase 3 Pivotal Trial in Graves' Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2647737697","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647737697?lang=en_us&edition=fundamental","pubTime":"2026-06-29 19:30","pubTimestamp":1782732601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nTUA3BXV5K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BHVN","BK4139","LU1093756325.SGD","LU1093756168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647375106","title":"Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Biohaven Ltd. (BHVN) and Praxis Precision Medicines (PRAX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2647375106","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647375106?lang=en_us&edition=fundamental","pubTime":"2026-06-29 18:50","pubTimestamp":1782730248,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Alnylam Pharma (ALNY), Biohaven Ltd. (BHVN) and Praxis Precision ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-alnylam-pharma-alny-biohaven-ltd-bhvn-and-praxis-precision-medicines-prax-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-alnylam-pharma-alny-biohaven-ltd-bhvn-and-praxis-precision-medicines-prax-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0109394709.USD","LU0114720955.EUR","XBI","PRAX","XLV","LU1093756168.USD","BK4585","LU0320765992.SGD","IE0002141913.USD","LU0882574055.USD","LU0128526141.USD","LU0029874061.USD","IE00B4R5TH58.HKD","BK4137","BK4581","BK4588","BK4139","BK4548","ALNY","IE00BFTCPJ56.SGD","HCSG","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","IE0009355771.USD","LU1093756325.SGD","LABU","LU0889565916.HKD","BHVN","IE00B2B36J28.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646632673","title":"Biohaven rises 7.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2646632673","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646632673?lang=en_us&edition=fundamental","pubTime":"2026-06-26 22:07","pubTimestamp":1782482824,"startTime":"0","endTime":"0","summary":"Biohaven (BHVN) is up 7.4%, or $1.13 to $16.47. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial new...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/biohaven-rises-7-4-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/biohaven-rises-7-4-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BHVN","BK4139","LU1093756325.SGD","LU1093756168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646133434","title":"U.S. Research Roundup-american Tower, H.B. Fuller Company, TD Synnex","url":"https://stock-news.laohu8.com/highlight/detail?id=2646133434","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646133434?lang=en_us&edition=fundamental","pubTime":"2026-06-26 15:06","pubTimestamp":1782457590,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-American Tower, H.B. Fuller Company, TD SynnexJune 26 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, includin","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260626:nL4N42Y0ET:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMH","AVTR","CSX","ALGT","BNY","DRI","ACNB","AIT","LU2413666699.HKD","CMC","TECH","AALG","DAL","ALLY","AVAV","LU0648001328.SGD","BNED","BRO","A","ACA","ALK","BDC","ESS","FDXF","FTH","BHVN","AR","AMT","CROX","EPR","CNTB","AAL","IE00BD4GTW91.USD","CUZ","BAC","EXPD","AVXX","DYN","LU0477156953.USD","CALY","GOLF","GH","LU0011850046.USD","CTSH","ESTC","LU0347712357.USD","AMAT","SNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646048238","title":"Biohaven's Troriluzole Could Drive Potential Upside if the Company Overcomes Regulatory Hurdles, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2646048238","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646048238?lang=en_us&edition=fundamental","pubTime":"2026-06-25 23:26","pubTimestamp":1782401212,"startTime":"0","endTime":"0","summary":"Biohaven's  troriluzole to treat neurodegenerative diseases could see up to a 100% upside if the company overcomes regulatory hurdles amid the US Food and Drug Administration's more sponsor-friendly stance, RBC Capital Markets said in a Thursday note.Considering shares as undervalued on epilepsy and degrader programs, the analysts said the drug candidate could make for an even more interesting setup for the stock.According to the note, factors that could support FDA leniency for troriluzole include its largely safe and well-tolerated data and design to target a rare disease with no approved treatments.RBC reiterated its outperform rating on the stock and adjusted its price target to $22 from $23.Price: 15.51, Change: +0.55, Percent Change: +3.68","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1093756325.SGD","BHVN","BK4139","LU1093756168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646967877","title":"RBC Capital Sticks to Their Buy Rating for Biohaven Ltd. (BHVN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2646967877","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646967877?lang=en_us&edition=fundamental","pubTime":"2026-06-25 19:35","pubTimestamp":1782387336,"startTime":"0","endTime":"0","summary":"In a report released today, Leonid Timashev from RBC Capital maintained a Buy rating on Biohaven Ltd., with a price target of $22.00. Timashev cove...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rbc-capital-sticks-to-their-buy-rating-for-biohaven-ltd-bhvn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rbc-capital-sticks-to-their-buy-rating-for-biohaven-ltd-bhvn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BHVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646794658","title":"Analysts Offer Insights on Healthcare Companies: Tenax Therapeutics (TENX), Biohaven Ltd. (BHVN) and BioLife Solutions (BLFS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2646794658","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646794658?lang=en_us&edition=fundamental","pubTime":"2026-06-25 17:50","pubTimestamp":1782381008,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Tenax Therapeutics (TENX), Biohaven Ltd. (BHVN) and ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-tenax-therapeutics-tenx-biohaven-ltd-bhvn-and-biolife-solutions-blfs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-tenax-therapeutics-tenx-biohaven-ltd-bhvn-and-biolife-solutions-blfs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","XBI","BK4121","BK4581","LU0128526141.USD","XLV","LU1093756325.SGD","BHVN","LU1093756168.USD","TENX","LU1169590202.USD","BLFS","LU1169589451.USD","BK4137","BK4198","HCSG","LABU","LU0029874061.USD","BK4139","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645860742","title":"Biohaven (BHVN) Is Up 22.2% After Advancing Multiple Immunology And Oncology Candidates To Pivotal Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2645860742","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645860742?lang=en_us&edition=fundamental","pubTime":"2026-06-24 14:30","pubTimestamp":1782282616,"startTime":"0","endTime":"0","summary":"Earlier in June, Biohaven Ltd. reported that it was moving several key pipeline assets into the clinic, including new studies of BHV-1510 for advanced or metastatic epithelial tumors and BHV-1530 for urothelial cancer and other tumors.\nThe company also outlined plans to start pivotal trials for BHV-1400 in IgA nephropathy and BHV-1300 for Graves’ disease, highlighting a broad push toward later-stage development across multiple immunology and oncology indications.\nWe’ll now examine how...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bhvn/biohaven/news/biohaven-bhvn-is-up-222-after-advancing-multiple-immunology","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bhvn/biohaven/news/biohaven-bhvn-is-up-222-after-advancing-multiple-immunology","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BHVN","LU1093756168.USD","BK4139","LU1093756325.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644088464","title":"Analysts Are Bullish on These Healthcare Stocks: uniQure (QURE), Biohaven Ltd. (BHVN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2644088464","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644088464?lang=en_us&edition=fundamental","pubTime":"2026-06-18 19:30","pubTimestamp":1781782212,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on uniQure (QURE), Biohaven Ltd. (BHVN) and Align Tech ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-uniqure-qure-biohaven-ltd-bhvn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-uniqure-qure-biohaven-ltd-bhvn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0889565916.HKD","BK4139","LU0109394709.USD","QURE","BHVN","LU1093756168.USD","LU0320765992.SGD","LU1093756325.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640189582","title":"Acting US FDA chief meets with rare disease groups to mend fences","url":"https://stock-news.laohu8.com/highlight/detail?id=2640189582","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640189582?lang=en_us&edition=fundamental","pubTime":"2026-06-04 03:10","pubTimestamp":1780513809,"startTime":"0","endTime":"0","summary":"Acting US FDA chief meets with rare disease groups to mend fencesRare disease groups seek regulatory clarity from FDA officialsDecisions by previous FDA chief disappointed such groupsActing commissioner seen as potential permanent nominee, sources sayBy Chris Prentice. 'SIGNIFICANT UNMET NEED'\"Meetings like this demonstrate FDA's continued commitment to address the real challenges facing the rare disease community and to advancing treatments in small-patient populations,\" Jeff Allen, CEO of Friends of Cancer Research, said in a statement.He said there were opportunities for novel trial designs and more efficient clinical trials, \"which could help accelerate new therapies to address areas of significant unmet need.\"A spokesperson for the Foundation for Angelman Syndrome Therapeutics, an advocacy group for patients with a rare neuro-genetic disorder, also confirmed attending the meeting. For diseases with small patient populations, regulatory clarity is needed to overcome challenges incl","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nL6N42B0TA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SRPU","IE00BJT1NW94.SGD","IE00B2B36J28.USD","BK4139","IE0009355771.USD","LU1093756168.USD","IE0002141913.USD","IE00BFTCPJ56.SGD","BK4585","SRPT","LU1093756325.SGD","BHVN","IE00BJJMRZ35.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640134908","title":"Is Biohaven’s PKM2 and Autoimmune Pipeline Progress Altering The Investment Case For Biohaven (BHVN)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2640134908","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640134908?lang=en_us&edition=fundamental","pubTime":"2026-06-03 17:20","pubTimestamp":1780478456,"startTime":"0","endTime":"0","summary":"Biohaven recently reported a series of pipeline advances, including first-in-human dosing of BHV-8100, its oral, brain-penetrant PKM2 modulator, alongside encouraging clinical data for autoimmune candidate BHV-1300 in Graves’ disease and BHV-1400 in IgA nephropathy.\nThese updates showcase Biohaven’s push into metabolically targeted neurology and precision immunology, positioning its platforms around disease-causing antibodies and energy metabolism rather than symptom control alone.\nNext,...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bhvn/biohaven/news/is-biohavens-pkm2-and-autoimmune-pipeline-progress-altering","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bhvn/biohaven/news/is-biohavens-pkm2-and-autoimmune-pipeline-progress-altering","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","LU1093756325.SGD","PRGS","LU2065732104.USD","BK4097","BHVN","LU1093756168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640951533","title":"Biohaven Starts First Human Trial of BHV-8100 for Neurological, Retinal and Inflammatory Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2640951533","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640951533?lang=en_us&edition=fundamental","pubTime":"2026-06-01 20:17","pubTimestamp":1780316220,"startTime":"0","endTime":"0","summary":"Biohaven  said Monday it has initiated first-in-human dosing of BHV-8100, an experimental oral, brain-penetrant PKM2 modulator being developed for neurological, retinal and inflammatory diseases.The Phase 1 study is evaluating the drug's safety, tolerability and pharmacokinetics in healthy volunteers, according to the company.Biohaven said early data showed BHV-8100 achieved projected therapeutic exposure levels, supported once-daily dosing and was generally well tolerated, with most adverse events reported as mild and spontaneously resolving.The company also highlighted preclinical findings from human brain studies showing BHV-8100 increased cerebral glucose utilization and lactate production by up to three times, suggesting improved brain energy metabolism.The effects were particularly pronounced in brains from patients with Alzheimer's disease, it said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BHV","BK4139","LU1093756168.USD","LU1093756325.SGD","BHVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640395626","title":"Biohaven starts first-in-human Phase 1 trial of oral PKM2 modulator BHV-8100","url":"https://stock-news.laohu8.com/highlight/detail?id=2640395626","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640395626?lang=en_us&edition=fundamental","pubTime":"2026-06-01 19:32","pubTimestamp":1780313579,"startTime":"0","endTime":"0","summary":"Biohaven began first-in-human dosing of BHV-8100, an oral, brain-penetrant PKM2 modulator, in a Phase 1 study in healthy participants.Early results have already been presented from the ongoing trial, showing tolerability consistent with continued dose escalation and a profile supporting once-daily dosing.Separate human brain model work also already reported showed signs of improved brain energy use, with a stronger effect in Alzheimer’s donor tissue.The program positions BHV-8100 as a potential platform asset across neurodegenerative, neuroinflammatory, retinal, and selected systemic inflammatory diseases.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biohaven Ltd. published the original content used to generate this news brief via PR","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nNDL63ZH7f:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1093756168.USD","BHVN","BK4139","LU1093756325.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639609290","title":"Analysts Are Bullish on These Healthcare Stocks: Biohaven Ltd. (BHVN), Abivax SA Sponsored ADR (ABVX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2639609290","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639609290?lang=en_us&edition=fundamental","pubTime":"2026-05-30 22:30","pubTimestamp":1780151414,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Biohaven Ltd. (BHVN) and Abivax SA Sponsored ADR (AB...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-biohaven-ltd-bhvn-abivax-sa-sponsored-adr-abvx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-biohaven-ltd-bhvn-abivax-sa-sponsored-adr-abvx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1093756168.USD","BHVN","BK4139","ABVX","LU1093756325.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638692531","title":"Analysts Conflicted on These Healthcare Names: MannKind (MNKD), Biohaven Ltd. (BHVN) and Precision BioSciences (DTIL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2638692531","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638692531?lang=en_us&edition=fundamental","pubTime":"2026-05-28 23:20","pubTimestamp":1779981606,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on MannKind (MNKD), Biohaven Ltd. (BHVN) and Precisio...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-mannkind-mnkd-biohaven-ltd-bhvn-and-precision-biosciences-dtil-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-mannkind-mnkd-biohaven-ltd-bhvn-and-precision-biosciences-dtil-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1093756325.SGD","BK4137","XBI","XLV","LU0029874061.USD","LU0128526141.USD","MNKD","BK4139","BK4584","BK4581","BK4585","LABU","BK4588","BHVN","HCSG","DTIL","LU1093756168.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.biohaven.com","stockEarnings":[{"period":"1week","weight":0.1665},{"period":"1month","weight":0.4021},{"period":"3month","weight":0.8913},{"period":"6month","weight":0.4197},{"period":"1year","weight":0.0739},{"period":"ytd","weight":0.4021}],"compareEarnings":[{"period":"1week","weight":-0.0238},{"period":"1month","weight":-0.0286},{"period":"3month","weight":0.1497},{"period":"6month","weight":0.056},{"period":"1year","weight":0.1914},{"period":"ytd","weight":0.069}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Biohaven Ltd., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with debilitating neurological and neuropsychiatric diseases in the United States. The company's pipeline products include BHV-7000, a potassium channel activator for the treatment of focal epilepsy; BHV-7010, a Kv7 channel modulator for the treatment of different neurological diseases; Troriluzole, a tripeptide prodrug that is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500, a low-trapping glutamate N-methyl-D-aspartate receptor antagonist for neuropathic pain; and Verdiperstat, an oral myeloperoxidase inhibitor, which is in Phase 3 clinical trial for the treatment of neurodegenerative diseases. It also offers Taldefgrobep Alfa, an anti-myostatin adnectin, which is in Phase 3 clinical trial for the treatment of spinal muscle atrophy; and BHV-1100 that is in Phase 1a/1b clinical trial for multiple myeloma patients. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut. Biohaven Ltd. is a subsidiary of Biohaven Pharmaceutical Holding Company Ltd.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.071849},{"month":2,"riseRate":0.222222,"avgChangeRate":-0.026101},{"month":3,"riseRate":0.222222,"avgChangeRate":-0.120539},{"month":4,"riseRate":0.555556,"avgChangeRate":0.027819},{"month":5,"riseRate":0.666667,"avgChangeRate":0.144578},{"month":6,"riseRate":0.6,"avgChangeRate":0.094185},{"month":7,"riseRate":0.555556,"avgChangeRate":0.010799},{"month":8,"riseRate":0.666667,"avgChangeRate":0.043364},{"month":9,"riseRate":0.777778,"avgChangeRate":0.09598},{"month":10,"riseRate":0.555556,"avgChangeRate":-0.072057},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.042561},{"month":12,"riseRate":0.555556,"avgChangeRate":0.054983}],"exchange":"NYSE","name":"Biohaven Pharmaceutical Holding Co Ltd.","nameEN":"Biohaven Pharmaceutical Holding Co Ltd."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Biohaven Pharmaceutical Holding Co Ltd.(BHVN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Biohaven Pharmaceutical Holding Co Ltd.(BHVN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Biohaven Pharmaceutical Holding Co Ltd.,BHVN,Biohaven Pharmaceutical Holding Co Ltd.股票,Biohaven Pharmaceutical Holding Co Ltd.股票老虎,Biohaven Pharmaceutical Holding Co Ltd.股票老虎国际,Biohaven Pharmaceutical Holding Co Ltd.行情,Biohaven Pharmaceutical Holding Co Ltd.股票行情,Biohaven Pharmaceutical Holding Co Ltd.股价,Biohaven Pharmaceutical Holding Co Ltd.股市,Biohaven Pharmaceutical Holding Co Ltd.股票价格,Biohaven Pharmaceutical Holding Co Ltd.股票交易,Biohaven Pharmaceutical Holding Co Ltd.股票购买,Biohaven Pharmaceutical Holding Co Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Biohaven Pharmaceutical Holding Co Ltd.(BHVN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Biohaven Pharmaceutical Holding Co Ltd.(BHVN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}